NEW YORK (GenomeWeb News) – Months removed from the commercial launch of its first test, Theranostics Health is targeting reimbursements as it looks to build a revenue stream for the test.

The Rockville, Md.-based firm launched the TheraLink HER Family Assay at the American Society of Clinical Oncology annual meeting in June, marking the next chapter in Theranostics' commercial build-out.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.